News

AMERISAFE Announces Special $3.00 Dividend for Shareholders

AMERISAFE Announces Special $3.00 Dividend for Shareholders

AMERISAFE Declares Special Dividend for Shareholders

AMERISAFE, Inc. (Nasdaq: AMSF), known for its focus on providing workers’ compensation insurance primarily in high-hazard industries, has made an exciting announcement that will please its shareholders. The company’s Board of Directors has officially declared a special cash dividend of $3.00 per share.

Details About the Dividend

This generous special cash dividend is set to be payable to shareholders of record as of December 6, 2024. Shareholders can expect to receive their dividend on December 13, 2024. This exciting announcement comes alongside the declaration of a regular quarterly dividend of $0.37 per share, also payable on December 13, 2024, to those who hold shares as of the same record date.

Company Leadership's Insights

G. Janelle Frost, the President and Chief Executive Officer of AMERISAFE, expressed enthusiasm regarding the special dividend. She stated, "We are pleased to declare this special dividend, highlighting our consistent underwriting expertise and financial discipline. Delivering value to shareholders by returning excess capital through special dividends is a key element of AMERISAFE’s long-term capital management strategy." This statement reinforces the company's commitment to maintaining a strong connection with its shareholders while promoting financial stability.

Historic Perspective on Dividends

Looking back over the past twelve years, AMERISAFE has demonstrated a robust commitment to returning value to its shareholders. The company has declared an impressive total of $47.37 per share in dividends during this period. This figure includes $11.12 in regular dividends and $36.25 in special dividends, showcasing a strong track record of shareholder returns.

Focus on High-Hazard Industries

AMERISAFE caters specifically to small and mid-sized employers engaged in industries that are considered high-hazard, including construction, trucking, logging and lumber, agriculture, and manufacturing. The company is actively marketing its services in 27 states, ensuring a broad reach and commitment to these critical industries.

Future Outlook

As AMERISAFE continues to navigate the challenges inherent in the workers’ compensation insurance market, it remains focused on achieving sustainable growth and enhancing shareholder value. With a proactive approach in managing excess capital, the recent declarations of special and regular dividends illustrate that the company is not only dedicated to its current shareholders but is also strategically positioning itself for future success.

Frequently Asked Questions

What is the amount of the special dividend declared by AMERISAFE?

The special dividend declared by AMERISAFE is $3.00 per share.

When will the special dividend be payable?

The special dividend will be payable on December 13, 2024, to shareholders of record as of December 6, 2024.

What is the regular quarterly dividend amount?

The Board also declared a regular quarterly dividend of $0.37 per share, payable on the same date as the special dividend.

What industries does AMERISAFE focus on?

AMERISAFE focuses on providing workers’ compensation insurance primarily for high-hazard industries including construction, trucking, logging, agriculture, and manufacturing.

What has been AMERISAFE's total dividend distribution over the last twelve years?

Over the past twelve years, AMERISAFE has declared a total of $47.37 per share in dividends, which consists of regular and special dividends.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
More News Articles